PBAC quietly says 'No' to subsidy

Gilead's hepatitis D treatment Hepcludex has finally been approved for use in Australia but the company has been delivered a blow in its reimbursement efforts with both the PBAC and MSAC rejecting its submissions.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here